NCT00458120 - Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Dengue Hemorrhagic Fever

Interventions

BIOLOGICAL

rDEN1delta30

Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.

BIOLOGICAL

rDEN2/4delta30(ME)

Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.

BIOLOGICAL

Placebo to rDEN1delta30 or rDEN2/4delta30(ME)

Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)

Trial Locations (1)

21205

Center for Immunization Research, Baltimore

All Listed Sponsors

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH